FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809817782> ?p ?o ?g. }

• W2809817782 endingPage "5882" @default.
• W2809817782 startingPage "5882" @default.
• W2809817782 abstract "Abstract Ciclopirox (CPX) is contained in a number of FDA-approved topical antifungal drug products as the free acid and olamine salt. CPX possesses anticancer activity in a number of in vitro and in vivo preclinical models. Its clinical utility is limited as an oral anticancer agent, however. The oral bioavailability of CPX is quite low due to extensive first pass effect. The poor water solubility of CPX and its olamine salt prevent formulation as an injectable drug product. Thirdly, dose-limiting gastrointestinal toxicities were observed following four times daily oral dosing of CPX in patients with advanced hematologic malignancies. Ciclopirox Prodrug (CPX-POM), in contrast, has demonstrated excellent bioavailability via injectable routes of administration. Here we describe the preclinical characterization of CPX-POM, a novel anticancer agent being developed for the treatment of non-muscle invasive (NMIBC) and muscle invasive (MIBC) bladder cancer. Following IV, SQ and IP administration to mice, CPX-POM is rapidly and completely metabolized to CPX in blood via circulating phosphatases. CPX and its major, inactive glucuronide metabolite are extensively eliminated in urine. At well-tolerated doses, steady-state urine concentrations of CPX exceed in vitro IC50 values in mice by 15-30 fold. CPX inhibited cell proliferation, colony formation, and bladdosphere formation in vitro in T24 (NMIBC) and 253JBV (MIBC) human cell lines in both concentration- and time-dependent manners with IC50 values of 2-4 µM. CPX exposure increased the percentage of NMIBC and MIBC cells arrested at the S and G0/G1 phases, and induced cell death. CPX exposure significantly reduced expression of genes at the mRNA level involved in cancer stem cell signaling pathways including Notch, Wnt, and Hedgehog. CPX was shown to inhibit bladder cancer cell growth in vitro by inhibiting the Notch 1 signaling pathway. The validated N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) chemical carcinogen mouse model of bladder cancer was employed to establish in vivo preclinical proof of principle for CPX-POM. Over the once-daily IP dose range of 25-200 mg/kg, CPX-POM treatment resulted in significant decreases in bladder weight, a clear migration to lower stage tumors, dose-dependent reduction in Ki67 and PCNA staining, as well as a reduction in PCNA-expressing cells. All CPX-POM doses were well tolerated with no evidence of toxicity to the urinary tract based on blinded pathologic evaluation. There were also dose-dependent decreases in Notch 1, Presenilin 1, and Hey 1 in bladder cancer tissues obtained from CPX-POM treated animals. Tumor response was similar, in vivo, following once-daily and three-times weekly CPX-POM administration. CPX-POM has received FDA clearance to proceed to Phase I, and is currently being evaluated in a first-in-human trial in patients with advanced solid tumors. Citation Format: Scott J. Weir, Partha Ranjarajan, Robyn Wood, Karl Schorno, Prabhu Ramamoorthy, Lian Rajweski, Kathy Heppert, Michael J. McKenna, William McCulloch, Greg A. Reed, Amanda Brinker, Michael J. Baltezor, Roy A. Jensen, John A. Taylor, Shrikant Anant. Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5882." @default.
• W2809817782 created "2018-07-10" @default.
• W2809817782 creator A5001135370 @default.
• W2809817782 creator A5002299630 @default.
• W2809817782 creator A5006831611 @default.
• W2809817782 creator A5016314692 @default.
• W2809817782 creator A5024030506 @default.
• W2809817782 creator A5027320590 @default.
• W2809817782 creator A5035668092 @default.
• W2809817782 creator A5043338847 @default.
• W2809817782 creator A5060965139 @default.
• W2809817782 creator A5072004481 @default.
• W2809817782 creator A5083641928 @default.
• W2809817782 creator A5084198940 @default.
• W2809817782 creator A5085346929 @default.
• W2809817782 creator A5086526874 @default.
• W2809817782 creator A5087699643 @default.
• W2809817782 date "2018-07-01" @default.
• W2809817782 modified "2023-10-16" @default.
• W2809817782 title "Abstract 5882: Bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer" @default.
• W2809817782 doi "https://doi.org/10.1158/1538-7445.am2018-5882" @default.
• W2809817782 hasPublicationYear "2018" @default.
• W2809817782 type Work @default.
• W2809817782 sameAs 2809817782 @default.
• W2809817782 citedByCount "2" @default.
• W2809817782 countsByYear W28098177822020 @default.
• W2809817782 countsByYear W28098177822021 @default.
• W2809817782 crossrefType "journal-article" @default.
• W2809817782 hasAuthorship W2809817782A5001135370 @default.
• W2809817782 hasAuthorship W2809817782A5002299630 @default.
• W2809817782 hasAuthorship W2809817782A5006831611 @default.
• W2809817782 hasAuthorship W2809817782A5016314692 @default.
• W2809817782 hasAuthorship W2809817782A5024030506 @default.
• W2809817782 hasAuthorship W2809817782A5027320590 @default.
• W2809817782 hasAuthorship W2809817782A5035668092 @default.
• W2809817782 hasAuthorship W2809817782A5043338847 @default.
• W2809817782 hasAuthorship W2809817782A5060965139 @default.
• W2809817782 hasAuthorship W2809817782A5072004481 @default.
• W2809817782 hasAuthorship W2809817782A5083641928 @default.
• W2809817782 hasAuthorship W2809817782A5084198940 @default.
• W2809817782 hasAuthorship W2809817782A5085346929 @default.
• W2809817782 hasAuthorship W2809817782A5086526874 @default.
• W2809817782 hasAuthorship W2809817782A5087699643 @default.
• W2809817782 hasConcept C108215921 @default.
• W2809817782 hasConcept C150903083 @default.
• W2809817782 hasConcept C181389837 @default.
• W2809817782 hasConcept C207001950 @default.
• W2809817782 hasConcept C2777288759 @default.
• W2809817782 hasConcept C2780035454 @default.
• W2809817782 hasConcept C71924100 @default.
• W2809817782 hasConcept C86803240 @default.
• W2809817782 hasConcept C98274493 @default.
• W2809817782 hasConceptScore W2809817782C108215921 @default.
• W2809817782 hasConceptScore W2809817782C150903083 @default.
• W2809817782 hasConceptScore W2809817782C181389837 @default.
• W2809817782 hasConceptScore W2809817782C207001950 @default.
• W2809817782 hasConceptScore W2809817782C2777288759 @default.
• W2809817782 hasConceptScore W2809817782C2780035454 @default.
• W2809817782 hasConceptScore W2809817782C71924100 @default.
• W2809817782 hasConceptScore W2809817782C86803240 @default.
• W2809817782 hasConceptScore W2809817782C98274493 @default.
• W2809817782 hasIssue "13_Supplement" @default.
• W2809817782 hasLocation W28098177821 @default.
• W2809817782 hasOpenAccess W2809817782 @default.
• W2809817782 hasPrimaryLocation W28098177821 @default.
• W2809817782 hasRelatedWork W1522159841 @default.
• W2809817782 hasRelatedWork W2053402936 @default.
• W2809817782 hasRelatedWork W2075198269 @default.
• W2809817782 hasRelatedWork W2086700810 @default.
• W2809817782 hasRelatedWork W2092357016 @default.
• W2809817782 hasRelatedWork W2279554812 @default.
• W2809817782 hasRelatedWork W3023756610 @default.
• W2809817782 hasRelatedWork W30436611 @default.
• W2809817782 hasRelatedWork W4281768328 @default.
• W2809817782 hasRelatedWork W88005891 @default.
• W2809817782 hasVolume "78" @default.
• W2809817782 isParatext "false" @default.
• W2809817782 isRetracted "false" @default.
• W2809817782 magId "2809817782" @default.
• W2809817782 workType "article" @default.